Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706424 | 0.98 | HRH3 (0.42) | HRH3PSMB1PSMB5PSMB2MAPT | |
| SCHEMBL5946007 | 0.86 | HRH3 (0.46) | HRH3MAPTALDH1A1 | |
| SCHEMBL5251321 | 0.85 | HRH3 (0.50) | HRH3 | |
| SCHEMBL8561716 | 0.83 | HRH3 (0.54) | HRH3MAPTL3MBTL1 | |
| SCHEMBL5946046 | 0.82 | ALDH1A1 (0.37) | HRH3ALDH1A1MEN1KMT2ALTA4H | |
| SCHEMBL5540209 | 0.80 | POLB (0.45) | HRH3MAPTALDH1A1POLBMEN1 | |
| SCHEMBL290317 | 0.80 | GLA (0.42) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL9534058 | 0.80 | KDM1A (0.32) | — | |
| SCHEMBL17135438 | 0.76 | HRH3 (0.39) | HRH3PSMB1PSMB5PSMB2MAPT | |
| SCHEMBL5294933 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4159330-A | ANTIALLERGENS | CARLO ERBA S.P.A. (IT) | 1979-06-26 | — | — | US | claimed |
| US-8084486-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-7960426-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7902232-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | ZOETIS SERVICES LLC | 2009-05-28 | — | — | US | disclosed |
| US-7514464-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| EP-1705989-B8 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| EP-1705989-B1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| EP-0174654-A2 | Carbonyl derivatives | CIBA-GEIGY AG (CH) | 1986-03-19 | — | — | EP | disclosed |
| EP-0174653-A2 | Phenylalkyl derivatives | CIBA-GEIGY AG (CH) | 1986-03-19 | — | — | EP | disclosed |
| EP-0171217-A2 | Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1986-02-12 | — | — | EP | disclosed |
| EP-0145956-A1 | Composés amidés | CIBA-GEIGY AG (CH) | 1985-06-26 | — | — | EP | disclosed |
| US-4497808-A | N-Oxide compounds useful in the treatment of cardiovascular ailments | CIBA-GEIGY CORPORATION (US) | 1985-02-05 | — | — | US | disclosed |
| EP-0111453-A1 | Amide derivatives | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| EP-0111455-A2 | Unsaturated lactones | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| EP-0089926-A2 | Pharmaceutical preparations of tetracycles containing nitrogen, and compounds of this type | CIBA-GEIGY AG (CH) | 1983-09-28 | — | — | EP | disclosed |
| EP-0083315-A2 | Pyridyl-N-oxides, processes for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1983-07-06 | — | — | EP | disclosed |
| US-4159330-A | ANTIALLERGENS | CARLO ERBA S.P.A. (IT) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | HRH3 127/4885PSMB1 3361/4885PSMB5 3172/4885 |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | HRH3 127/4885PSMB1 3361/4885PSMB5 3172/4885 |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A43, CYP3A4, CYP4X1 | HRH3 1235/4885PSMB1 4110/4885PSMB5 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.